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Abstract
Recently, we demonstrated that the transcription factors HNF6 and FOXA2 function as key regulators in human colorectal
liver metastases. To better understand their proposed inhibitory crosstalk, the consequences of functional knockdown of
FOXA2 on HNF6 and C/EBPa activity were investigated in the human colon Caco-2 and HepG2 carcinoma cell lines.
Specifically, siRNA-mediated gene silencing of FOXA2 repressed transcript expression by .80%. This resulted in a
statistically significant 6-, 3-, 4-, and 8-fold increase in mRNA expression of HNF6 and of genes targeted by this transcription
factor, e.g., HSP105B, CYP51, and C/EBPa, as determined by qRT-PCR. Thus, functional knockdown of FOXA2 recovered
HNF6 activity. Furthermore, with nuclear extracts of Caco-2 cells no HNF6 DNA binding was observed, but expression of
HNF1a, FOXA2, FOXA3, and HNF4a protein was abundant. We therefore transfected a plasmid encoding HNF6 into Caco-2
cells but also employed a retroviral vector to transfect HNF6 into HepG2 cells. This resulted in HNF6 protein expression with
DNA binding activity being recovered as determined by EMSA band shift assays. Furthermore, by flow cytometry the
consequences of HNF6 expression on cell cycle regulation in transfected cells was studied. Essentially, HNF6 inhibited cell
cycle progression in the G2/M and G1 phase in Caco-2 and HepG2 cell lines, respectively. Here, proliferation was reduced by
80% and 50% in Caco-2 and HepG2 cells, respectively, as determined by the BrdU labeling assay. Therefore functional
knockdown of FOXA2 recovered HNF6 activity and inhibited growth of tumor-cells and may possibly represent a novel
therapeutic target in primary and secondary liver malignancies.
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Introduction
Colorectal cancer is the second leading cause of cancer death in
the world. Nearly 800,000 new cases are diagnosed each year, and
approximately 500,000 deaths have been estimated annually for
the US alone [1,2]. As of today, the molecular basis of metastatic
spread of colonic tumor cells into the liver is unknown. There is
need to improve an understanding of disease causing mechanisms
as to develop novel and improved treatment opportunities.
Recently, we reported the regulation of some major hepatic
nuclear factors in primary human colon cancer and colorectal liver
metastases [3]. We found HNF6 expression to be absent in healthy
colon or primary colon cancer, but observed abundant expression
of unacetylated HNF6 in nuclear extracts of colorectal liver
metastases. However, unacteylated HNF6 was unable to bind to
targeted DNA sequences and to activate genes regulated by this
factor. Because of its known interaction with HNF6 expression of
FOXA2 was investigated, which we found to be highly
upregulated in colorectal liver metastases. There is also evidence
for HNF6 to serve as a coactivator protein thereby enhancing
FOXA2 transcription, but FOXA2 represses HNF6 transcription
and genes targeted by this transcription factor.
Based on our initial results and findings reported by others we
wished to probe for the role of FOXA2 in the regulation of HNF6
activity in colorectal liver metastases [4,5,6]. We therefore studied
the consequences of functional knockdown of FOXA2 on HNF6
DNA binding activity in the human colon cancer cell line Caco-2.
We also investigated the role of HNF6 on cell cycle regulation in
HepG2 cells, as this human hepatoma cell line is also devoid of the
HNF6 protein. Indeed, HNF6 may function as a master regulatory
protein in primary and secondary liver malignancies. Overall, our
study aimed for an improved understanding of an inhibitory
crosstalk between FOXA2 and HNF6 in metastasizing colon
cancer and to utilize this knowledge for the development of an
siRNA mediated therapeutic approach.
Materials and Methods
Cell culture
Caco-2 cells and HepG2 cells were obtained from the European
Collection of Cell Cultures (ECACC, Salisbury, UK) and were
cultured using conditions reported by Lampen et al. (Caco-2 cells)
and Wilkening et al. (HepG2 cells) [7,8].
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RNA was isolated with the RNeasy Mini Kit (Quiagen)
according to the manufacturer’s recommendation while cDNA
synthesis was carried out as reported [3].
Quantitative PCR analysis with the Roche Light Cycler
System
Real time PCR was done with the LightCyclerH according to
the manufacture’s recommendation (Roche Diagnostics, Penz-
berg, Germany) with oligonucleoitides previously reported [3].
SYBRH Green I was used as a fluorescent dye to determine the
amplified PCR product after each cycle. The length of PCR
products was checked by gel electrophoresis. Gene expression of
FOXA2, C/EBPalpha, CYP51, HSP105B and HNF6 was
determined with primers reported in [3] in a standard PCR
reaction containing 50 ng of DNA, 4.0 mM MgCl2 and 2 mlo f
LightCycler DNA Master hybridisation mixture (LightCycler
DNA Master Hybridization Probes, Roche Diagnostics Inc) in a
total volume of 20 ml. The reaction was started with a
denaturation step at 95uC for 20 seconds and amplification was
performed for 50 cycles denaturation (95uC for 0 seconds; ramp
rate 20uC per second), annealing (58uC for 8 seconds, ramp rate
20uC per second) and extension (72uC for 18 seconds, ramp rate
20uC per second). In the case of the mitochondrial ATPase the
reaction was started with a denaturation step at 95u C for 20
seconds and amplification was performed for 50 cycles of
denaturation (95uC for 0 seconds; ramp rate 20uC per second),
annealing (55uC for 8 seconds, ramp rate 20uC per second) and
extension (72uC for 18 seconds, ramp rate 20uC per second). PCR
products were identified by monitoring DNA melting curves in the
glas capillary. At the end of each extension phase fluorescence was
observed and used for quantitative measurements within the linear
range of amplification yielding calculated concentrations as
relative units. Exact quantification was achieved by serial dilution
with cDNA produced from total RNA extracts using serial dilution
steps. The obtained values were divided by those of mitochron-
drial ATPase to obtain expression values relative to the
housekeeping gene.
Isolation of nuclear extracts
Nuclear extracts from Caco-2 cells were isolated by the
modified method of Dignam et al. [9]. Eleven days after seeding
cells were washed twice with ice-cold PBS, scraped into
microcentrifuge tubes and centrifuged for 5 min at 20006 g,
4uC. Cell pellets were resuspended in lysis buffer (10 mM Tris
pH 7.4, 2 mM MgCl2, 140 mM NaCl, 1 mM DTT, 4 mM
Pefabloc, 1% Aprotinin, 40 mM b-glycerophosphate, 1 mM
sodiumorthovanadate and 0.5% TX100) at 4uC for 10 min
(300 ml for 16107 cells), transferred onto one volume of 50%
sucrose in lysis buffer and centrifuged at 140006 g and 4uC for
10 min. Nuclei were resuspended in Dignam C buffer (20 mM
Hepes pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 1 mM DTT, 4 mM Pefabloc, 1% Aprotinin,
40 mM b-glycerophosphate, 1 mM sodiumorthovanadate, 30 ml
for 16107 cells) and gently shaked at 4uC for 30 min. Nuclear
debris was removed by centrifugation at 140006 ga t4 uC for
10 min. Protein concentrations were determined according to the
method of Smith et al. [10]. The extracts were aliquoted and
stored at 270uC.
Whole Tissue Extracts
Tissues were frozen in liquid nitrogen immediately after
explantation and stored at 280uC until further analysis. Prior to
protein extraction, about 150 mg of each frozen tissue were
ground using pre-chilled mortar and pestle. Then the tissue was
sonicated (UP 200 s, Dr. Hielscher) in 0.5 ml lysis buffer (5 mol/l
urea, 2 mol/l thiourea, 40 mmol/l Tris, 4% CHAPS, 100 mmol/l
DTT, 0.5% BioLyte 3–10; Biorad) on ice. After centrifugation at
12000 rpm the supernatant was recovered and the remaining
pellet was resuspended in 0.5 ml lysis buffer (as described above).
Extracts were combined and stored in aliquots at280uC until
analysis. Total protein concentrations of extracts were determined
with the HCL-modified Bradford protein assay (Bio-Rad Protein
Assay Dye Reagent Concentrate, Biorad).
Western blotting experiments
Western immunoblotting was done as follows: Nuclear protein
(30 mg) extracts of Caco-2 cell cultures were denaturated at 95uC
for 5 min, followed by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) on 12% polyacrylamide gels, and
blotted onto a polyvinylidene difluoride membrane (NEN,
Dreieich, Germany) at 350 mA for 2 h in a buffer containing
400 mM glycine and 50 mM Tris (pH 8.3). Non-specific binding
sites were blocked with Rotiblock (Roth, Germany) in 1x TBS
buffer. After electroblotting of proteins, membranes were incu-
bated with polyclonal antibodies for HNF1 alpha (Santa Cruz
sc6548), FOXA2 (Santa Cruz sc6554), FOXA3 (Santa Cruz
sc5360), HNF4 alpha (Santa Cruz sc 6556), and HNF6 (kind gift of
Dr. R. H. Costa, Chicago, Illinois, USA) for 1 h and washed 3
times with 1x TBS buffer containing 0.1% Tween-20 (Roth,
Germany). Subsequently, the membranes were incubated with a
1:5000 diluted anti-a rabbit antibody (Chemicon, Hofheim,
Germany) for 1 h at room temperature, followed by 3 successive
washes with 1x TBS buffer containing 0.1% Tween-20 (Roth,
Germany). Immunoreactive proteins were visualized with a
chemiluminescence reagent kit (NEN, Dreieich, Germany)
according to the manufacturer’s instructions, and bands were
scanned with the Kodak Image Station CF 440 and analyzed
using the Kodak 1D 3.5 imaging software (Eastman Kodak
Company, USA).
Design of EMSA-oligos for HNF6 binding sites in
promotor sequences of human genes
Known binding sites of HNF6 (ONECUT1) were collected
from the TRANSFAC database, (www.biobase.de). The motive
search was done with TRANSFAC release 9.4. To retrieve
promoters of human genes the TRANSPro release 2.1 was
employed. In the case of HNF6 the position weight matrix
(M00639; V$HNF6_Q6) was used that was originally constructed
on the basis of 13 known binding sequences of HNF6 targeted
promoters. The design for the oligo probes for HNF6 and FOXA2
was optimized as previously reported [3].
Annealing of synthetic oligonucleotides and [32P]
labeling
Oligonucleotides were designed enharboring high affinity
HNF6 consensus site in gene specific promoters. Oligonucleotides
were annealed at a concentration of 19.2 pM ? mL
21 in 200 mM
Tris (pH 7.6), 100 mM MgCl2 and 500 mM NaCl at 80uC for
10 min, then cooled slowly to room temperature overnight and
stored at 4uC. Annealed oligonucleotides were diluted to 1:10 in
Tris-EDTA buffer (1 mM EDTA, 10 mM Tris, pH 8.0) and
labelled using [32P] ATP (Amersham Biosciences Europe GmbH,
Freiburg, Germany, 250 mCi, 3,000 Ci ? mM
21) and T4
polynucleotide kinase (New England Biolabs GmbH, Frankfurt
am Main, Germany). End-labelled probes were separated from
FOXA2 and HNF6 in Colon Cancer
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(Amersham Biosciences Europe GmbH, Freiburg, Germany) and
eluted in a final volume of 100 mL.
Electrophoretic mobility band shift assay (EMSA)
EMSA assays were carried out as described in [11]. Briefly, 5 mg
of CaCo2 nuclear extract were incubated with the binding buffer
consisting of 25 mM HEPES (pH 7.6), 5 mM MgCl2,3 4m M
KCl, 2 mM DTT, 2 mM Pefablock (Roche Diagnostics GmbH,
Mannheim, Germany), 0.5 mL aprotinin (2.2 mg ? mL
21, Sigma-
Aldrich Chemie GmbH, Taufkirchen, Germany), 50 ng poly (dl-
dC) and 80 ng bovine serum albumin (PAA Laboratories GmbH,
Co ¨lbe, Germany). The binding reaction was carried out for
20 min on ice, and free DNA and DNA-protein complexes were
resolved on a 6% polyacrylamide gel. Furthermore, a specific
HNF6 and/or HNF4a antibody (Santa Cruz Biotechnology Inc.,
Heidelberg, Germany) was added to the reaction mix 10 min
before addition of the labelled probe. In the case of NGN3, no
commercial antibody is available. Thus, a competition assay at
x100 and x500-fold access of unlabeled oligonucelotide probe
specific for NGN3 was used. Gels were blotted to Whatman 3 MM
paper, dried under vacuum, exposed to imaging screens (Imaging
Screen-K, Bio-Rad Laboratories GmbH, Munich, Germany) for
autoradiography overnight at room temperature and analyzed
using a phosphor imaging system (Molecular Imager FX pro plus;
Bio-Rad Laboratories GmbH, Munich, Germany) and the
Quantity One Version 4.2.2 software (Bio-Rad Laboratories
GmbH, Munich, Germany).
Viral expression system for HNF6
Based on a method of Soneoka et al. a three-plasmid expression
system was used for the production of retroviral vetors [12].
Specifically, this murine retroviral system employs the Vesicular
Stomatitis Virus G protein (VSV-G wt) in the packaging of viral
particles. Note, VSV-G protein mediates the viral entry via a
ubiquitously expressed receptor on target cell surface. The viral
particle production is performed in HEK293T cells with a
protocol based on the transient packaging method established by
Soneoka et al. [12]. In this system genes encoding the structural
proteins, the envelope protein and the gene of interest are
expressed by different plasmids. The three-plasmids are transfect-
ed simultaneously into the packing HEK293T cells. The viral
particles contain only parts of the parental organism including the
59LTR, 39LTR and the packing signal Psi. Since genes encoding
the structural proteins are not transfected with the viral particle,
the produced viruses are infectious but replication-incompetent.
The viral particles permitted transfer of the HNF6 coding
sequence to HepG2 cells.
Transfection of HNF6 into Caco-2 cells and the HepG2
human hepatoma cell line
To confirm the proposed inhibitory cross-talk of FOXA2 and
HNF6 and to determine its effect on gene expression and cell cycle
regulation the colon carcinoma cell line Caco-2 cells and the
human hepatoma cell line HepG2 was transfected with a HNF6
containing plasmid. The plasmid was the kind gift of Dr.
Le ´maigre, Universite ´ catholique de Louvain, Belgium. Important-
ly, healthy colonic epithelium and colonic cancers do not express
HNF6 but expression of unacetylated HNF6 was observed in
nuclear extracts of colorectal liver metastases [3]. Therefore, it
became necessary to express HNF6 in target cell lines to enable
mechanistic studies. To be able to investigate the inhibitory cross
talk of the FOXA2 and HNF6 transcription factor proteins Caco-2
cells were transfected with an HNF6 plasmid and Lipofectamine
2000 (Invitrogen), that is a cationic-lipid transfection reagent
according to the manufacture’s recommendation. In the case of
HepG2 cells a retroviral transfection plasmid was used to improve
the level of HNF6 expression in HepG2 cells. Note, the expression
of HNF6 by use of the retroviral transfection plasmids was similar
to healthy liver (data not shown) when the protocol of Soneoka et
al. was used as described above [12].
Briefly, two vectors were received from the laboratory of Dr.
Le ´maigre to enable efficient transfection of HNF6 (Hormone and
Metabolic Research Unit, Institute of Cellular Pathology,
Universite ´ catholique de Louvain, Brussels, Belgium). HNF6 was
cloned into (a) V-831, pCMV-MCS (Stratagene), a mammalian
expression vector containing a multiple cloning site (MCS), a
CMV promoter, and other elements for high-level gene expres-
sion; (b) V-894, pIRES2-EGFP (Clontech, discontinued), which
contains an internal ribosome entry site (RES; 1,2) of the
encephalomyocarditis virus (ECMV) between the MCS and the
enhanced green fluorescent protein (eGFP) coding region. This
permitted both the gene of interest (cloned into the MCS) and the
eGFP gene to be translated from a single bicistronic mRNA.
Plasmid DNA was isolated using the Maxiprep endotoxin-free kit
(Qiagen). The DNA was precipitated with EtOH at 4000 rpm for
90 min and 2x washings at 4000 rpm for 60 min. The HNF6
insert was confirmed by RLFP with BamHI/EcoRI for V-894 and
BamHI/XhoI for V-831. The product was approximately 1.6 kb
after restriction enzyme digestion.
Cells (200,000 per 35-mm well) were seeded in a six-well culture
plate containing 2 ml per well of Dulbeco’s modified Eagles
medium (DMEM) with fetal calf serum (end conc. 8.7%),
glutamine (end conc. 2x), and penicillin/streptomycin (end conc.
2 x). Cells were grown at 37uC in a humidified 5% CO2/approx.
95% air atmosphere. The medium was prepared as follows:
500 ml DMEM +50 ml of 10% FCS +12 ml of 100x L-glutamine
and 12 ml of 100x penicillin/streptomycin.
Prior to transfection (1 h), DMEM medium was removed and
cells were washed with PBS. The medium was then replaced with
Opti-MEM I medium, a versatile chemically defined medium
formulated to significantly reduce the amount of serum required
for cultivating mammalian cells in vitro. It is a modification of
Eagle’s Minimal Essential Medium, buffered with HEPES and
sodium bicarbonate, and supplemented with hypoxanthine,
thymidine, sodium pyruvate, L-glutamine or GlutaMAX, trace
elements, and growth factors. The protein level is minimal
(15 mg/ml), with insulin and transferrin being the only protein
supplements. Phenol red is included at a reduced concentration as
a pH indicator. Transfection was carried out using Lipofectamine
2000 (Invitrogen), a cationic-lipid transfection reagent according
to the manufacture’s recommendation. Efficiency of transfection
was assed qualitatively by fluorescent microscopy of which an
example is given in Fig. 1a.
In the case of HepG2, the HNF6 containing plasmid (see above)
was cloned into the pczCFG5.1MCS vector, which is one
necessary component of the three-vector transduction system. In
order to produce replication-deficient retroviral particles genes
encoding the structural and envelope proteins, as well as the
HNF6 coding plasmid were transfect into the human embryonic
kidney 293T packaging cells. Then, the viral particles derived
from the HEK293T cell line were harvested and used to transfect
HNF6 into HepG2 cells as detailed below.
Protocol for packaging of retroviral vectors
Packaging of retroviral particles was carried out with HEK293T
cells at a density of 4610
6 cells per 10 cm dish. At day 1 usually
FOXA2 and HNF6 in Colon Cancer
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transfection of the HEK293T cells with the retroviral vectors was
achieved using the PEI protocol as originally described by
Soneoka et al. [12]. Here the plasmid pHIT60 encodes gag-pol
whereas the plasmid pcz-VSV-Gwt encodes the envelope protein
from Vesicular Stomatitis Virus while plasmid pcz-CFG2-HNF6
Figure 1. HNF6 protein expression and DNA binding activity in the human colon carcinoma cell line Caco-2. A. Image of fluorescent
microscopy of HNF6 plasmid-transfected into Caco-2 cells, magnification 20x; B. empty vector control; C. electromobility band shift assay (EMSA)
demonstrating HNF6 DNA binding activity with nuclear extracts isolated from healthy human liver (positive control), empty vector control and HNF6-
transfected Caco-2 cells; addition of an antibody specific for HNF6 shifted bands as denoted by the circle.
doi:10.1371/journal.pone.0013344.g001
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without HNF6 were the kind gift of Dr. Achim Renne,
Department of Neurological Surgery, University of Dresden,
Germany.
To induce activity of the CMV promotor the transfection
medium was replaced with medium containing sodium butyrate at
a final concentration of 10 mM. Note, polybrene enhances viral
adherence on cells. The medium from the HEK293T cells was
collected and filtered trough 0.2 mm filters. Polybrene was added
at a concentration of 8 mg/ml and the HepG2 cells were incubated
with this medium over night to induce HNF6 expression.
Small-interference FOXA2 RNA (siRNA)-mediated
knockdown in Caco-2
Caco-2 cells were cultured to 70–80% of confluence and were
transfected with 3 different FOXA2 siRNA probes (see FOXA2
Stealth
TM
(Invitrogen) as originally designed by Invitrogen. These
probes were used according to the manufacture’s recommenda-
tions and allowed verification of phenotypic changes as well as
control of off-target effects. Transfection efficiency was controlled
by the Block-iT
TM Alexa FluorH Red Fluorescent Oligo (Invitro-
gen). This red-labeled dsRNA oligomer is designed for use in
RNAi experiments to facilitate assessment and optimization of
dsRNA oligonucleotides delivery into mammalian cells by use of
cationic lipids (Lipofectamine 2000). In Fig. 2 images of individual
FOXA2 siRNA probes transfections and of BLOCK-IT Alexa
Fluor Red Fluorescent Oligo as well as a negative control are
depicted. Notably, Caco-2 cells were incubated with various
FOXA2 siRNA oligonucleotide for 48 h to down regulate FOXA2
gene expression. FITC-labeled scrambled siRNA (Control-FITC
block-it fluorescent Oligo #2013, Invitrogen, Germany) was used
as a negative transfection control.
Measurement of RNAi activity
Quantitative RT-PCR was applied to determine the gene
expression of FOXA2 after siRNA knock-down and of HNF6 and
Figure 2. Functional knockdown of FOXA2 in the human colon carcinoma cell line Caco-2. A. Images of fluorescent microscopy of Caco-2
cells transfected with different FOXA2 siRNA probes and empty vector control. Note, the transfection efficiency was similar amongst the three
different siRNA probes while functional knock down of FOXA2 was best with one probe termed FOXA2HSS142473 (details are given by the
manufacture, Invitrogen, Paisley, Great Britain); G01, G03 and G05 refer to three independent individual experiments; B. FOXA2 and HNF6 gene
expression after functional knockdown of FOXA2 in three independent experiments, *p,0.05 when compared to untreated Caco-2 cells; C. Gene
expression of HNF6 and FOXA2 in untreated Caco-2 cells of n=3 independent experiments, *p,0.05. HNF6 gene expression is significantly less when
compared to FOXA2 gene expression.
doi:10.1371/journal.pone.0013344.g002
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CYP51 using the oligonucleotide probes and the protocol
described above.
Cell cycle and cell proliferation assay
Cells were plated in 96-well microtiter plates at a density of
5000 cells/well 24 h prior to treatment. Cell cycle and cell
proliferation were measured using the CycleTest Plus Reagent and
the BrdU labeling kit according to the manufacture’s recommen-
dations (see below).
Cell cycle analysis
The effects of HNF6 expression on the cell cycle were studied by
flow cytometry. Cells were plated in six-well sterile plastic plates at
a density of 10
5 22610
5 cells/well and were allowed to attach for
24 h. Then cells were collected by trypsinization and DNA
staining was done with the CellTest Plus Reagent Kit (Becton
Dickinson Immunocytometry Systems, San Jose, California, USA).
According to the manufacturer’s instruction cells were washed
with a buffer solution containing sodium citrate, sucrose, and
dimethyl sulfoxide (DMSO). Then cells were incubated according
to a three-step sequence: a) 10 min at room temperature with
solution A containing trypsin in a spermine tetrahydrochloride
detergent buffer (to digest cell membranes and cytoskeleton); b)
10 min at room temperature with solution B containing a trypsin
inhibitor and ribonuclease A in citrate-stabilizing buffer with
spermine terahydrochloride (to inhibit the trypsin activity and to
digest RNA); c) 15 min in the refrigerator with solution C
containing propidium iodide and spermine tetrahydrochloride in
citrate-stabilizing buffer. Analysis was performed using a FACScan
(Becton Dickinson GmbH Immunozytometrische Systeme, Hei-
delberg, Germany), and data analysis was carried out with
CELLQuest software, while cell cycle distribution was determined
using the Modifit software (Verity Software House, Inc.).
BrdU cell proliferation assay
BrdU incorporation was measured using the BrdU Cell
Proliferation Assay (Merck, Darmstadt, Germany) according to
the manufacturer’s instructions. Cells were labeled with BrdU
(1:100) for the last 4 h of incubation. Cells were washed, fixated,
and incubated with mouse anti-BrdU antibody (1:100; 100 ml/
well) for 1 h at room temperature. Antibody labeling was detected
by secondary peroxidase-coupled goat-anti-mouse antibody
(1:1000, 100 ml/well; 30 min at room temperature). After washing,
peroxidase substrate was added for 15 min. The peroxidase
reaction was stopped by adding 100 ml 2.5N sulfuric acid, and
absorbance was measured using dual wavelengths of 450 and
595 nm.
Statistical analysis
The Wilcoxon signed rank test and the student’s t-test was used
to determine significance with P,0.05 being statistically signifi-
cant.
Results
Recovery of HNF6 expression in Caco-2 cell cultures
Initially, studies were carried out with the human colon
adenocarcinoma cell line Caco-2. Unlike colorectal liver metas-
tases which do express HNF6, primary colonic cancer and Caco-2
cells do not express detectable levels of this protein. We therefore
employed an HNF6-containing plasmid and studied DNA binding
activity of the coded protein upon transfection. The choice of
vector permitted imaging of HNF6 (cloned into the MCS) by
fluorescence microscopy. As shown in Fig. 1A Caco-2 cells were
successfully transfect with HNF6 but the transfection efficacy
varied amongst individual experiments, while Fig. 1B exemplifies
empty vector transfections. To further probe for HNF6 binding
activity we performed EMSA band shift assays. As depicted in
Fig. 1C and unlike controls we observed HNF6 nuclear protein
expression and DNA binding activity in transfected Caco-2cells.
Here healthy human liver nuclear protein extracts served as
control. Notably, expression level of HNF6 protein transfected into
Caco-2 cells was similar to that of human liver. Addition of an
antibody that specifically recognizes HNF6 completely removed
the protein bound to an HNF6 optimized oligonucleotide probe
therefore confirming specificity of the assay. With nuclear extracts
of HNF6 transfected Caco-2 cells additional bands are visible
suggesting protein-protein interactions at an HNF6 optimized
oligonucleotide probe.
siRNA-mediated functional knockdown of FOXA2
Evidence from our own laboratory and other investigators
suggested a regulatory loop for FOXA2 with HNF6 [3,13].
Indeed, HNF6 functions as a coactivator protein to potentiate the
transcriptional activity of FOXA2 [13]. Furthermore, it was shown
earlier that a C/EBPa-HNF6 protein complex stimulates HNF6
and FOXA2 transcriptional activity through recruitment of the
CBP coactivator protein [14].
To probe for an inhibitory FOXA2-HNF6 crosstalk a small-
interference RNA-mediated knockdown of FOXA2 in Caco-2
cells was carried out at a confluency of about 70%. In Fig. 2A
images of transfections with different siRNA probes and the empty
vector control are depicted. Essentially the transfection efficiency
of the different RNAi probes was similar as was that of the
BLOCK-IT ‘‘empty vector control’’ which was used to monitor
the efficiency of transfection. Based on qRT-PCR a statistically
significant nearly 80% knockdown efficiency of FOXA2 gene
expression was achieved. This resulted in reduced FOXA2 protein
expression as illustrated in Fig. 3 albeit at different levels, when
individual siRNA probes were compared. Indeed, a total of 6
individual experiments were carried out. In 4 out of 6 experiments
the data were robust and reliable suggesting that only some probes
are efficient in silencing FOXA2 gene expression. Fig. 2B depicts
the results of FOXA2 and HNF6 gene expression of at least n=3
independent siRNA experiments. Notably, functional knockdown
of FOXA2 resulted in a significant 4-fold increase in HNF6 gene
expression. For comparison the expression of FOXA2 and HNF6
in untreated CaCo-2 cells is depicted in Fig. 2 C. With Caco-2
cells FOXA2 gene expression was nearly twice that of HNF6 (see
Fig. 2C). Note, in Caco-2 cells HNF6 transcripts were not
translated into protein.
By qRT-PCR the gene expression of HNF6 and FOXA2 was
studied in cells transfected with the HNF6 plasmid. As shown in
Fig. 4A plasmid gene expression of HNF6 varied amongst
individual experiments and depended on the transfection efficien-
cy but was up to 120-fold increased, as compared to the empty
vector control. Note, efficient HNF6 plasmid expression resulted
in a reduced FOXA2 gene expression but the effects differed
amongst individual experiments (see. Fig. 4B).
Furthermore, the DNA binding of FOXA2 and HNF6 was
investigated in CaCo-2 cells after functional knock down of
FOXA2. As shown in Fig. 5A DNA binding activity of FOXA2 to
an optimized FOXA2 oligonucleotide probe was significantly
reduced after functional knock down of FOXA2, while in HNF6
plasmid expressing Caco-2 cells FOXA2 DNA binding was
significantly increased (see panel A). As depicted in panel B the
DNA binding of HNF6 (not FOXA2!) to an optimized HNF6
FOXA2 and HNF6 in Colon Cancer
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13344Figure 3. Western blotting of FOXA2 (A), HNF4a (B) and Actin (C) in CaCo-2 cells and human liver. Note, the HNF4a served as a positive
control while Actin was used as loading control. Human liver nuclear extracts served as additional positive control. One of the siRNA oligonucleotides
reduced FOXA2 protein significantly (see siRNA probe 3). This probe also affected expression of HNF4a while HNF6 plasmid expression had no effect
on FOXA2 or HNF4a protein expression. M=molecular weight standard; LG=nuclear extracts of healthy liver; LM=nuclear extracts of colorectal liver
metastases; PK=nuclear extracts of untreated Caco-2 cells; lanes 1-3 refers to different siRNA probes.
doi:10.1371/journal.pone.0013344.g003
FOXA2 and HNF6 in Colon Cancer
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13344oligonucleotide probe was significantly increased in HNF6 plasmid
expression CaCo-2 cells, whereas no DNA binding was observed
in untreated or FOXA siRNA treated CaCo-2 cells. This is of no
surprise, as CaCo-2 cells do not express HNF6 protein at
detectable level. Notably, we recently demonstrated that epithe-
lium of healthy human colon does not express HNF6 mRNA
transcripts and protein expression levels [15]. In this study Lehner
et al. investigated the gene expression patterning of HNF6 in
different segments of the human intestine and demonstrated a
significant local and segmental differences in the expression of
HNF6 and other liver enriched transcription factors in the human
intestine which impacts epithelial cell biology of the gut [15].
Consequently, FOXA2 siRNA does not recover HNF6 DNA
binding activity in unmodified CaCo-2 cells as these cells do not
express HNF6. However, the DNA binding activity of HNF6 in
CaCo-2 cell HNF6 plasmid expressing cells was significantly
reduced when a FOXA2 antibody was used in EMSA band shift
assays with an HNF6 optimized oligonucleotide probe (see Fig. 5
panel C). Thus, the previously described inhibitory cross talk
between HNF6 and FOXA2 can be recapitulated at the level of
DNA binding activity in HNF6 plasmid expressing CaCo-2 cells.
Overall, a protein-protein interaction amongst FOXA2 and
HNF6 to an HNF6 optimized oligonucleotide probe is evidenced
(see lane 4 of Fig. 5C).
Results from Western blotting experiments are depicted in
Figure 3. Notably, FOXA2 siRNA Probe 3 caused a significant
reduction in FOXA2 and a minor reduction in HNF4alpha
expression while actin served as a loading control.
Based on the study of Odom et al. [16], who employed a CHIP-
chip protocol to identify HNF6 target genes, three genes targeted
by this factor were selected. As shown in Fig. 6 siRNA-mediated
functional knockdown of FOXA2 resulted in a 3-fold, 4-fold, and
8-fold increase in gene expression of HSP105B, CYP51, and C/
EBPa, respectively.
Cell cycle and BrdU labeling experiments with the Caco-2
and HepG2 human cancer cell lines
To delineate a possible role of HNF6 on cell division BrdU
labeling and cell cycle analysis studies were carried out. As
compared to the empty vector, HNF6 transfection caused a highly
significant cell cycle arrest in the G2/M phase in Caco-2 cells
(Fig. 7A) and in the G1 an S-phase of HepG2 cells, respectively
(Fig.7B). Likewise, cell proliferation was significantly reduced by
80% and 50% in HNF6-transfected Caco-2 cells (Fig. 7C) and
HepG2 cells (Fig. 7D).
Discussion
Colorectal liver metastases is a major cause of cancer morbidity
and this study aimed for an improved understanding of an
inhibitory cross talk of FOXA2 and HNF6 in secondary liver
malignancies. Specifically, the carcinoma cell lines Caco-2 and
HepG2 enabled mechanistic investigations into FOXA2 on HNF6
nuclear protein activity. Because HNF6 is not expressed in healthy
colonic epithelium and colonic cancers but in colorectal liver
metastases it was necessary to employ an experimental strategy by
which HNF6 is transfected into cancer cell lines as to permit
mechanistic studies. Thus, HNF6 was transfected by different
means to the cancer cell lines Caco-2 and HepG2 which are colon
and human hepatoma cell lines. The transfected protein was stable
and DNA binding activity of HNF6 could be evidenced by EMSA
band shift assays. Notably, we used the same optimized
oligonucleotide probes to investigate DNA binding of HNF6 as
reported in our initial study on human colorectal liver metastases
[3]. In this study no DNA binding of HNF6 was observed with
extract of nuclear proteins isolated from colorectal metastatic liver
tumors, even though abundant expression of the HNF6 protein
was seen. In fact, HNF6 DNA binding was selectively abrogated
through lack of posttranscriptional acetylation [3]. In the present
study we evidenced transfection of the HNF6 protein in Caco-2
cell cultures to result in HNF6 DNA binding activity (see Fig. 1C).
Note, no HNF6 DNA binding activity was observed with control
Caco-2 cell cultures (see Fig. 1C). Because of the hypothesized
inhibitory crosstalk between FOXA2 and HNF6 we investigated
the consequences of functional knockdown of FOXA2 on HNF6
gene expression. As shown in Fig. 2B an approximately 4-fold
increase in HNF6 gene expression was determined in FOXA2
siRNA-transfected Caco-2 cell cultures. Thus, FOXA2 knock-
down recovered HNF6 activity.
Essentially, there are two seminal studies on the transcriptional
activity of HNF6 and its association with the FOXA2 protein
[17,18]. There is evidence for HNF6 to serve as co-activator
protein to enhance FOXA2 transcription, whereas FOXA2
Figure 4. qRT-PCR of HNF6 and FOXA2 gene expression in HNF6 plasmid expressing CaCo-2 cells. Shown are n=3 independent
experiments (denoted by V1 to V3) where HNF6 plasmid expression resulted in significant increase in HNF6 mRNA transcripts (see panel A). The
efficiency of HNF6 transfection varied considerably. In HNF6 transfected Caco-2 cells expression of FOXA2 mRNA transcripts was investigated (see
panel B). FOXA2 gene expression was reduced. Each bare represents the mean of at least n=3 independent measurements.
doi:10.1371/journal.pone.0013344.g004
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through inhibition of HNF6 DNA binding activity. It was
demonstrated that on the FOXA2 promoter the HNF6 and
FOXA2 protein interaction stimulates recruitment of the p300/
CBP histone acetyltransferase proteins, which interacts with the
RNA polymerase II transcriptional machinery [18]. Conversely,
binding of FOXA2 and its physical interaction with HNF6
inhibited HNF6 dependent transcriptional activation of targeted
genes, as only acetylated HNF6 displayed DNA binding activity
[18]. In the study of Poll et al. the regulation of the HNF6
promoter was studied in detail thereby delineating transcription
factor binding sites [17]. Through DNase I footprinting experi-
ments binding sites for the transcription factors Sp1 and STAT5
were identified in the HNF6 promoter. In addition, the
investigators identified an intronic enhancer termed I3. Such
footprint analysis defined transcription factor binding sites for C/
EBP, FOXA, HNF6, NF1 and HNF1/PDX1 proteins. In
subsequent luciferase gene driven HNF6 promoter activity studies
it was demonstrated that mutation of FOXA and HNF1 binding
sites in the intronic region I3 reduced transcriptional activity of the
HNF6 gene. From these results it was concluded that FOXA and
HNF1 proteins are critical regulators of HNF6 expression and that
binding of FOXA2 modifies chromatin structure to permit access
of other transcription factors, as detailed in the study of Cirillo
et al. [19].
Taken collectively, FOXA2 likely controled expression of HNF6
through physical interaction with HNF6 that has been shown to
bind to an intronic sequence I3 thereby controlling expression of
genes at least in pancreatic precursor cells of the endoderm, as
reported in detail by Poll et al. [17]. Nonetheless, there is
controversy regarding an interaction between HNF6 and FOXA2
in the liver. Indeed, in the study of Rubins et al. hepatocyte
specific gene ablation of FOXA2 was achieved. Here, HNF6
activitiy at targeted promoters in vivo appeared to be independent
of the FOXA2 protein [20], while in the study of Rubins et al. it
was also demonstrated that FOXA2 does synergize with HNF6 at
some HNF6 targeted gene promoters to possibly facilitate
activation of transcription. There is clear evidence for FOXA
Figure 5. Electromobility band shift assay with nuclear extracts isolated from either untreated or FOXA2 siRNA or HNF6 plasmid
expression cells. Panel A: Depicted is the DNA binding activity of FOXA2 to an optimized probe. Specificity of the DNA binding is confirmed by
adding a FOXA2 antibody which resulted in a shifted band. A circle marks the shifted band. Note, siRNA of FOXA2 resulted in a marked reduced DNA
binding of the FOXA2 protein to its cognate recognition site. Importantly, FOXA2 DNA binding activity is strongly increased in HNF6 plasmid
expressing cells. Panel B: Depicted is the DNA binding activity of HNF6 to an optimized probe. Specificity of the DNA binding is confirmed by adding
a HNF6 antibody, which resulted in a shifted band which is marked by a circle. In untreated cells no HNF6 DNA binding is observed and for such cell
cultures FOXA2 siRNA did not influence HNF6 DNA binding activity. In HNF6 plasmid expressing cells high HNF6 DNA binding activity is observed.
Panel C: Depicted is the DNA binding activity of HNF6 transfected Caco-2 cell nuclear extracts to an optimized probe. A marked reduction in DNA
binding activity of HNF6 is observed when an antibody recognizing FOXA2 is added concomitantly. Likewise, addition of antibodies specific for HNF6
and FOXA2 reduced HNF6 DNA binding activity to an HNF6 optimized oligonucleotide probe.
doi:10.1371/journal.pone.0013344.g005
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access of other transcription factors to induce gene transcription.
Possibly, the association between HNF6 and FOXA2 functions in
a cell type specific manner and may be restricted to some targeted
gene promoters. Likewise, in the study of Rausa et al.
coimmunoprecipitation experiments demonstrated that the
HNF6 Cut domain was sufficient to interact with the FOXA2
protein an that retention of the HNF6 Cut and Homeodomain
was required for interaction with the p300/CBP histone
acetyltransferase proteins to induce transcriptional synergy [18].
Notably, these studies were carried out in HepG2 cells as utilized
in the present study where HNF6 was transfected into HepG2 and
CaCo-2 cells.
We further demonstrated gene expression of HNF6-regulated
genes, namely, HSP105B, CYP51, and C/EBPa to be significantly
upregulated upon siRNA-mediated functional knockdown of
FOXA2. Indeed, functional knockdown of FOXA2 induced
transcriptional regulation of C/EBPa, a transcription factor that
causes arrests of cell proliferation through direct inhibition of
Cdk2 and Cdk4 [21]. In the study of Odom et al., who employed a
CHIP-chip protocol to identify HNF6 target genes, it was
demonstrated that C/EBPalpha is a bonafide target of this protein
[16]. Furthermore, an association between HNF6 and C/
EBPalpha had been reported by Yoshida et al. [14]. Here, a C/
EBPalpha and HNF6 protein complex stimulated HNF6-depen-
dent transcriptional activity through recruitment of the CBP co-
activator protein in HepG2 cells. There is evidence for C/
EBPalpha to physically interact with HNF6 but HNF6 also targets
the C/EBPalpha promoter to induce transcriptional activation.
In this regard it is of paramount importance that C/EBPalpha
inhibited cell growth through direct repression of E2F mediated S-
phase gene transcription. Specifically, the study of Slomiany et al.
demonstrated the physical association of C/EBPalpha with S-
phase gene promoters and its transcriptional repression [22].
Consequently, C/EBPalpha inhibited cell growth. It is also of
considerable interest that the cyclin-dependend kinase 2 was
highly significantly upregulated (p,0.01) in tissue extracts of
colorectal liver metastases of male and female patients (see Lehner,
Klempnauer and Borlak 2010, manuscript in preparation) and it
was shown earlier that C/EBPalpha interacts directly with cdk2 to
arrest cell proliferation through inhibition of this kinase. Thus, C/
EBPalpha inhibited cdk2 activity by blocking the association of
cdk2 with cyclins to bring about growth arrest.
Consequently, HNF6 links C/EBPa to cell cycle regulation.
Here we show inhibition of FOXA2 to stimulate HNF6 activity, as
evidenced by cell cycle analysis and BrdU cell proliferation assays,
all of which demonstrates inhibition of growth, i.e. cell cycle arrest
at the G1 and the G2/M phase (see Fig. 7). However, the role of
Figure 6. Gene expression of FOXA2 and of the HNF6 target genes HSP105B (see panel A), CYP51 (see panel B) and C/EBPa (see
panel C) in the human carcinoma cell line Caco-2 after siRNA-mediated functional knockdown of FOXA2. Results represents the mean
of n=3 individual experiments; G01, G03 and G05 refer to individual experiments. *p,0.05 when compared to untreated CaCo-2 cells.
doi:10.1371/journal.pone.0013344.g006
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Some investigators suggest HNF6 to function as a coactivator
protein to potentiate the transcriptional activity of FOXA2 [18],
whereas others report HNF6 function to be independent of
FOXA2 [20]. Here we show FOXA2 gene expression to be
reduced in HNF6 plasmid expressing CaCo-2 cells (see Fig. 4).
Previously it was shown that patients diagnosed with secondary
liver malignancies display significant regulation of FOXA2 and
HNF6 in nuclear extracts of colorectal liver metastases. We found
HNF6 DNA binding to be selectively abrogated as a result of
impaired HNF6 acetylation and interaction with FOXA2. In line
with our previous clinical study and our recent study on the gene
expression patterning of liver enriched transcription factors in
different segments of the human intestine we now report the
HNF6 protein to be below the level of detection in Caco-2 cell
cultures, even though expression of HNF6 mRNA could be
evidenced, but was approximately half of that observed for
FOXA2 (see Fig. 2C). Note, expression of HNF6 protein
expression in Caco-2 and HepG2 cells is below the level of
detection. It is of considerable importance that siRNA-mediated
functional knockdown of FOXA2 resulted in transcriptional
activation of HNF6 and of genes targeted by this factor. Our
findings with the human colon cancer cell line Caco-2 agreed well
with previous studies on the human hepatoma HepG2 cell line co-
transfected with HNF6 or its deletion mutants as well as FOXA1,
FOXA2, or FOXA3 TATA-luciferase reporter constructs [18]. In
the present study we transfected HNF6 into HepG2 cells. This
resulted in cell cycle arrest in the G1 phase. Likewise, cell
proliferation was significantly reduced in the BrdU labeling assay,
therefore confirming an important inhibitory role of HNF6 in the
regulation of cell cycle progression and cell proliferation of cancer
cells. Overall, results from the human Caco-2 and HepG2 cells
agreed well. Importantly, FOXA2 protein was strongly induced in
human colorectal liver metastases [3] and the findings of the
present study are highly suggestive for an inhibitory crosstalk of
FOXA2 and HNF6 in colorectal liver metastases. There is a report
to suggest HNF6 activity to be independent of FOXA2 [20] and in
this conditional FOXA2 knockout mouse model targeted expres-
sion of HNF6 genes appeared to be independent of the presence of
FOXA2. In our previous clinical study, however, HNF6 was not
expressed in healthy or cancerous colon, but was abundantly
expressed in nuclear extracts of colorectal liver metastatic tissue.
Nonetheless, HNF6 DNA binding activity was selectively abro-
gated in colorectal liver metastases because the protein was not
acetylated and this posttranslational modification is a prerequisite
for DNA binding activity at targeted promoters. As shown in the
Figure 7. Cell cycle analysis and BrdU labeling in Caco-2 and HepG2 cells. A. Cell cycle analysis of Caco-2 and HNF6-transfected Caco-2 cells
by flow cytometry. B. Cell cycle of HepG2 and HNF6-transfected HepG2 cells by flow cytometry. C. BrdU labeling of the human colon cancer cell line
Caco-2 transfected with HNF6. P,0.05 when compared to untransfected cells. D. BrdU labeling of the human liver cancer cell line HepG2 transfected
with HNF6. P,0.05 when compared to untransfected cells.
doi:10.1371/journal.pone.0013344.g007
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cells and blocks cell cycle progression. Further evidence stems from
siRNA-mediated functional knockdown of FOXA2, which
recovered HNF6 activity and caused cell cycle arrest.
Overall, HNF6 stimulated C/EBPa-dependent transcription
[14] and resulted in an approximately 6-fold increased in C/EBPa
gene expression in transfected Caco-2 cell cultures. A functional
link between recovery of HNF6 activity and C/EBPa dependent
cell cycle regulation was established by cell cycle analysis and
BrdU labeling assay. The fact that HNF6 gene expression was
increased as a result of FOXA2 siRNA-mediated functional
knockdown provides further evidence for an inhibitory crosstalk
between FOXA2 and HNF6 as there is conclusive evidence for C/
EBPa to bring about growth arrest by inhibiting Cdk2 and Cdk4
[21].
In conclusion, siRNA mediated functional knockdown of
FOXA2 increased transcriptional activity of HNF6 and of genes
targeted by this factor. Recovery of HNF6 activity resulted in cell
cycle arrest in human tumor gut epithelium and liver parenchyma
cancer cell lines. Our study demonstrates a significant role of
FOXA2 in colorectal liver metastases, which makes FOXA2 an
interesting target in the therapy of colorectal liver metastases.
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